Skip to main content
Caplight Logo









Tranquis Therapeutics

Tranquis Therapeutics

Private
Redwood City, CaliforniaHealthcare & Life Scienceshttps://tranquis.com

Last Round

Series A

Jul 9, 2020

Total Funding Raised

$30M

Company Overview

Tranquis Therapeutics is a biopharmaceutical company focused on developing innovative small molecule drugs that reprogram dysfunctional myeloid immune cells to transform the treatment of neurodegenerative and aging-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyimmuno-neurologysmall molecule therapeuticsneurodegenerative diseasedrug discoverybiotech startupaging-related diseasespreclinical developmentmyeloid cell modulationdrug pipelinebiopharmaclinical-stage biotechtherapeutic assetsblood-brain barrier

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tranquis Therapeutics Comparables

Compare Tranquis Therapeutics with similar companies based on industry and business-model similarity.

Tranquis Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Monument Biosciences
86%
NeuroTherapia, Inc.
86%
Muna Therapeutics
82%

Tranquis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 9, 2020

Tranquis Therapeutics Investors

Notable investors and investment history

Tranquis Therapeutics investors
InvestorRounds
Remiges VenturesSeries A
Correlation VenturesSeries A
SR OneSeries A
Vivo CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 9, 2020

    $30M round led by Remiges Ventures and SR One.

Tranquis Therapeutics Filings

Explore SEC and related filing metadata, where available.

Tranquis Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Tranquis Therapeutics's valuation, stock price, and market status.

Is Tranquis Therapeutics a public or private company?

Tranquis Therapeutics is a private company.

What is the current stock price of Tranquis Therapeutics?

Tranquis Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Tranquis Therapeutics worth (valuation)?

Valuation information for Tranquis Therapeutics is not publicly available.

Can I buy Tranquis Therapeutics stock?

Tranquis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Tranquis Therapeutics's last funding round?

Tranquis Therapeutics's most recent funding round was Series A on July 9, 2020.

Who are the main investors in Tranquis Therapeutics?

Key investors in Tranquis Therapeutics include Remiges Ventures, SR One.

Will Tranquis Therapeutics IPO soon?

No public IPO plans have been announced for Tranquis Therapeutics.

How can I track Tranquis Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Tranquis Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersRedwood City, California
Employee Range3
Year Founded2016
Last FundingJul 9, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?